Last reviewed · How we verify
Usual cardiovascular medications
Usual cardiovascular medications is a Small molecule drug developed by Imperial College London. It is currently in Phase 3 development for Hypertension, Coronary artery disease. Also known as: Usual cardiovascular disease prevention medication.
This drug class typically works by modulating various pathways involved in cardiovascular function, such as blood pressure regulation, heart rate, and lipid metabolism.
This drug class typically works by modulating various pathways involved in cardiovascular function, such as blood pressure regulation, heart rate, and lipid metabolism. Used for Hypertension, Coronary artery disease.
At a glance
| Generic name | Usual cardiovascular medications |
|---|---|
| Also known as | Usual cardiovascular disease prevention medication |
| Sponsor | Imperial College London |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
These medications can act through different mechanisms, including blocking receptors that increase heart rate and blood pressure, inhibiting enzymes that contribute to hypertension, or reducing cholesterol levels to prevent atherosclerosis.
Approved indications
- Hypertension
- Coronary artery disease
Common side effects
- Dizziness
- Fatigue
Key clinical trials
- Nutritional Ketosis Marfan (NA)
- A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events (NA)
- Evaluation Of A Virtual Cardiology Program To Improve Outcomes After Acute Decompensated Heart Failure (NA)
- Australasian Resuscitation In Sepsis Evaluation: FLUid or Vasopressors In Emergency Department Sepsis (PHASE3)
- The GUARDIAN Pilot Trial (NA)
- Catheter Ablation Versus Anti-arrhythmic Drugs for Ventricular Tachycardia (NA)
- PAUSE: Sick Day Medication Management Mobile App Study (NA)
- Resistance Exercise Training on Vascular and Physical Function in Postmenopausal Women (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Usual cardiovascular medications CI brief — competitive landscape report
- Usual cardiovascular medications updates RSS · CI watch RSS
- Imperial College London portfolio CI
Frequently asked questions about Usual cardiovascular medications
What is Usual cardiovascular medications?
How does Usual cardiovascular medications work?
What is Usual cardiovascular medications used for?
Who makes Usual cardiovascular medications?
Is Usual cardiovascular medications also known as anything else?
What development phase is Usual cardiovascular medications in?
What are the side effects of Usual cardiovascular medications?
Related
- Manufacturer: Imperial College London — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension
- Indication: Drugs for Coronary artery disease
- Also known as: Usual cardiovascular disease prevention medication
- Compare: Usual cardiovascular medications vs similar drugs
- Pricing: Usual cardiovascular medications cost, discount & access